Skip to content
Tasmar(tolcapone)
Tasmar (tolcapone) is a small molecule pharmaceutical. Tolcapone was first approved as Tasmar on 1997-08-27. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against catechol O-methyltransferase.
Download report
Favorite
SARS-CoV-2 Interaction
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Tasmar (generic drugs available since 2015-03-26)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tolcapone
Tradename
Company
Number
Date
Products
TASMARBausch Health CompaniesN-020697 RX1998-01-29
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
tasmarNew Drug Application2020-10-02
tolcaponeNDA authorized generic2020-10-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N04: Anti-parkinson drugs
N04B: Dopaminergic agents
N04BX: Other dopaminergic agents in atc
N04BX01: Tolcapone
HCPCS
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G2011
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Obsessive-compulsive disorderD009771EFO_0004242F42212
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AlcoholismD000437EFO_0003829F10.133
Tobacco use disorderD014029F17213
Traumatic brain injuriesD000070642S0622
Brain injuriesD001930S06.922
GamblingD005715F63.0112
Impulsive behaviorD007175112
SchizophreniaD012559EFO_0000692F2011
Attention deficit disorder with hyperactivityD001289EFO_0003888F9011
Chronic brain injuryD02020811
Neurocognitive disordersD019965F0911
Show 2 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients22
AmyloidosisD000686EFO_1001875E8511
Decision makingD00365711
Executive functionD05634411
NeuroblastomaD009447EFO_000062111
Cocaine-related disordersD019970F1411
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Brain concussionD001924S06.011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTOLCAPONE
INNtolcapone
Description
Tolcapone is benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase. It has a role as an EC 2.1.1.6 (catechol O-methyltransferase) inhibitor and an antiparkinson drug. It is a member of benzophenones, a member of 2-nitrophenols and a member of catechols.
Classification
Small molecule
Drug classcatechol-O-methyltransferase (COMT) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(C(=O)c2cc(O)c(O)c([N+](=O)[O-])c2)cc1
Identifiers
PDB3S68
CAS-ID134308-13-7
RxCUI72937
ChEMBL IDCHEMBL1324
ChEBI ID63630
PubChem CID4659569
DrugBankDB00323
UNII IDCIF6334OLY (ChemIDplus, GSRS)
Target
Agency Approved
COMT
COMT
Organism
Homo sapiens
Gene name
COMT
Gene synonyms
NCBI Gene ID
Protein name
catechol O-methyltransferase
Protein synonyms
epididymis secretory sperm binding protein Li 98n, testicular tissue protein Li 42
Uniprot ID
Mouse ortholog
Comt (12846)
catechol O-methyltransferase (Q91XH4)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,457 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tasmar, Tolcapone
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
100,387 adverse events reported
View more details